Bram Wieskopf, MD
Internal Medicine · Woodstock, GANPI 1164472577
Payments from drug & device makers
Across 808 payments — averaging $27,066 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$17.2M
- Regeneron$1.5M
- AstraZeneca$1M
- AbbVie$900K
- Pfizer$435K
- Seqirus USA Inc$309K
- plus $482K from 21 others
Across 14 payments — averaging $27,285 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$382K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 96 | $17,200,630 |
| Regeneron | 212 | $1,498,210 |
| AstraZeneca | 11 | $1,044,244 |
| AbbVie(2 entities) | 79 | $900,356 |
| Pfizer | 34 | $434,567 |
| Seqirus USA Inc | 118 | $309,317 |
| Noven Pharmaceuticals, Inc. | 16 | $181,658 |
| Esperion Therapeutics, Inc. | 127 | $79,279 |
| Sanofi US Services Inc. | 11 | $67,529 |
| Genentech, Inc. | 8 | $43,283 |
| GRT US Holding, Inc. | 16 | $36,839 |
| GSK | 14 | $29,729 |
| Novo Nordisk AS | 5 | $13,933 |
| Lexicon Pharmaceuticals, Inc. | 2 | $12,010 |
| Sanofi | 1 | $9,500 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $6,629 |
| Lilly USA, LLC | 8 | $783 |
| Amgen | 16 | $417 |
| Radius Health, Inc. | 5 | $213 |
| Sanofi-aventis U.S. LLC | 10 | $134 |
| Novo Nordisk | 7 | $118 |
| Amarin Pharma, Inc. | 4 | $60 |
| Boehringer Ingelheim | 3 | $57 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$21,869,556 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Woodstock
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
- David KavtaradzeCordele$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.